임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-13 23:46
논문번호 98
논문제목(영문) Two-year clinical outcome after carvedilol-loaded stent implantation in patients with coronary artery disease.
국내외구분 국내 SCI여부 SCI
연구책임자역할 교신저자
주저자명 Kim HK
교신저자명 Jeong MH
공동저자명 Kim HK, Hong YJ, Jeong MH, Kim W, Kim SS, Ko JS, Lee MG, Sim DS, Park KH, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC;
게제년월일 2010-03-23
ISSN 1226-3303
Impact Factor 1.426
학술지명 The Korean journal of internal medicine
서지사항 0집 / 26권 / 1호,   페이지(41 - 46)
요약초록문
(Abstract) 입력		 BACKGROUND/AIMS:
Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration. The aim of this study was to investigate the beneficial effects of carvedilol-loaded stents on 2-year clinical outcomes after stent implantation in patients with coronary artery disease.
METHODS:
We performed a prospective trial with male subjects to compare the safety and effects of carvedilol-loaded BiodivYsio® stents implanted into 20 patients with those of bare-metal BiodivYsio® stents implanted into 21 patients for de novo coronary lesions. The primary end point was the degree of neointimal hyperplasia, which was measured by intravascular ultrasound (IVUS) 6 months after the procedure; the secondary end point was major adverse cardiac events (MACE) at 2 years after implantation. All carvedilol and control stents were deployed successfully.
RESULTS:
A 2-year follow-up was completed for 19 patients (95%) in the carvedilol stent group and 20 patients (95%) in the control stent group. IVUS showed a trend toward a larger luminal area (6.86 ± 2.59 vs. 5.47 ± 1.52 mm², p = 0.267), smaller neointimal area (1.34 ± 0.70 vs. 2.40 ± 1.73 mm², p = 0.18), and reduced net decrease in luminal area (-0.78 ± 0.97 vs. -1.89 ± 1.78 mm², p = 0.106) in the carvedilol stent group compared with the control stent group, respectively. There were no significant differences in the incidence of MACE (10.5 vs. 30.0%, respectively, p = 0.132) between the groups at 2 years after stent implantation. Stent thrombosis did not occur in either group after 2 years.
CONCLUSIONS:
The carvedilol-loaded stents tended to inhibit neointimal hyperplasia without the occurrence of cardiac death, myocardial infarction, or stent thrombosis at 2-year follow-up.
파일  C98.+Korean+J+Intern+Med.+2011;26(1)41-46..pdf (426.7K) DATE : 2021-05-25 13:15:14